Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism: Pooled Individual Results of Two Randomised Controlled Trials
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism : Pooled Individual Results of Two Randomised Controlled Trials. / Zijlstra, Laurien E.; Jukema, J. Wouter; Westendorp, Rudi G. J.; Du Puy, Robert S.; Poortvliet, Rosalinde K. E.; Kearney, Patricia M.; O'Keeffe, Linda; Dekkers, Olaf M.; Blum, Manuel R.; Rodondi, Nicolas; Collet, Tinh-Hai; Quinn, Terence J.; Sattar, Naveed; Stott, David J.; Trompet, Stella; den Elzen, Wendy P. J.; Gussekloo, Jacobijn; Mooijaart, Simon P.
In: Frontiers in Endocrinology, Vol. 12, 674841, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Levothyroxine Treatment and Cardiovascular Outcomes in Older People With Subclinical Hypothyroidism
T2 - Pooled Individual Results of Two Randomised Controlled Trials
AU - Zijlstra, Laurien E.
AU - Jukema, J. Wouter
AU - Westendorp, Rudi G. J.
AU - Du Puy, Robert S.
AU - Poortvliet, Rosalinde K. E.
AU - Kearney, Patricia M.
AU - O'Keeffe, Linda
AU - Dekkers, Olaf M.
AU - Blum, Manuel R.
AU - Rodondi, Nicolas
AU - Collet, Tinh-Hai
AU - Quinn, Terence J.
AU - Sattar, Naveed
AU - Stott, David J.
AU - Trompet, Stella
AU - den Elzen, Wendy P. J.
AU - Gussekloo, Jacobijn
AU - Mooijaart, Simon P.
PY - 2021
Y1 - 2021
N2 - BackgroundThe cardiovascular effects of treating older adults with subclinical hypothyroidism (SCH) are uncertain. Although concerns have been raised regarding a potential increase in cardiovascular side effects from thyroid hormone replacement, undertreatment may also increase the risk of cardiovascular events, especially for patients with cardiovascular disease (CVD).ObjectiveTo determine the effects of levothyroxine treatment on cardiovascular outcomes in older adults with SCH.MethodsCombined data of two parallel randomised double-blind placebo-controlled trials TRUST (Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial) and IEMO80+ (the Institute for Evidence-Based Medicine in Old Age 80-plus thyroid trial) were analysed as one-stage individual participant data. Participants aged >= 65 years for TRUST (n=737) and >= 80 years for IEMO80+ (n=105) with SCH, defined by elevated TSH with fT4 within the reference range, were included. Participants were randomly assigned to receive placebo or levothyroxine, with titration of the dose until TSH level was within the reference range. Cardiovascular events and cardiovascular side effects of overtreatment (new-onset atrial fibrillation and heart failure) were investigated, including stratified analyses according to CVD history and age.ResultsThe median [IQR] age was 75.0 [69.7-81.1] years, and 448 participants (53.2%) were women. The mean TSH was 6.38 +/- SD 5.7 mIU/L at baseline and decreased at 1 year to 5.66 +/- 3.3 mIU/L in the placebo group, compared with 3.66 +/- 2.1 mIU/L in the levothyroxine group (pConclusionTreatment with levothyroxine did not significantly change the risk of cardiovascular outcomes in older adults with subclinical hypothyroidism, irrespective of a history of cardiovascular disease and age.
AB - BackgroundThe cardiovascular effects of treating older adults with subclinical hypothyroidism (SCH) are uncertain. Although concerns have been raised regarding a potential increase in cardiovascular side effects from thyroid hormone replacement, undertreatment may also increase the risk of cardiovascular events, especially for patients with cardiovascular disease (CVD).ObjectiveTo determine the effects of levothyroxine treatment on cardiovascular outcomes in older adults with SCH.MethodsCombined data of two parallel randomised double-blind placebo-controlled trials TRUST (Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial) and IEMO80+ (the Institute for Evidence-Based Medicine in Old Age 80-plus thyroid trial) were analysed as one-stage individual participant data. Participants aged >= 65 years for TRUST (n=737) and >= 80 years for IEMO80+ (n=105) with SCH, defined by elevated TSH with fT4 within the reference range, were included. Participants were randomly assigned to receive placebo or levothyroxine, with titration of the dose until TSH level was within the reference range. Cardiovascular events and cardiovascular side effects of overtreatment (new-onset atrial fibrillation and heart failure) were investigated, including stratified analyses according to CVD history and age.ResultsThe median [IQR] age was 75.0 [69.7-81.1] years, and 448 participants (53.2%) were women. The mean TSH was 6.38 +/- SD 5.7 mIU/L at baseline and decreased at 1 year to 5.66 +/- 3.3 mIU/L in the placebo group, compared with 3.66 +/- 2.1 mIU/L in the levothyroxine group (pConclusionTreatment with levothyroxine did not significantly change the risk of cardiovascular outcomes in older adults with subclinical hypothyroidism, irrespective of a history of cardiovascular disease and age.
KW - cardiovascular disease
KW - levothyroxine
KW - randomised controlled trial
KW - subclinical hypothyroidism
KW - older adults
KW - ADULTS
KW - ASSOCIATION
KW - PROTOCOL
U2 - 10.3389/fendo.2021.674841
DO - 10.3389/fendo.2021.674841
M3 - Journal article
C2 - 34093444
VL - 12
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
SN - 1664-2392
M1 - 674841
ER -
ID: 271613320